Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: Phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets Clinical microbiology and vaccines

BMC Microbiology

Volumn 15, Issue 1, 2015, Pages

  Law, Dennis K S ^a   Lefebvre, Brigitte ^b   Gilca, Rodica ^b,c   Deng, Saul ^a   Zhou, Jianwei ^a   De Wals, Philippe ^b,c   Tsang, Raymond S W ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

4CMenB protein vaccine targets; Invasive Neisseria meningitidis

Indexed keywords

ANTISERUM; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; PORIN A; PROTEIN FHBP; PROTEIN NADA; PROTEIN NHBA; PROTEIN VARIANT; UNCLASSIFIED DRUG; 4CMENB VACCINE; ADHESIN; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; MENINGOCOCCUS VACCINE; NADA PROTEIN, NEISSERIA MENINGITIDIS; PORIN; PORIN PROTEIN, NEISSERIA;

ANTIGEN EXPRESSION; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CANADA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FREQUENCY; GENETIC CODE; GENOTYPE; HUMAN; INVASIVE SPECIES; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; MOLECULAR CLONING; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN TARGETING; SEROTYPE; SPECIES DIVERSITY; WHOLE CELL; CLASSIFICATION; GENETIC VARIATION; GENETICS; GENOTYPING TECHNIQUE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MENINGITIS, MENINGOCOCCAL; MICROBIOLOGY; PREVALENCE; QUEBEC; SEROTYPING;

NEISSERIA MENINGITIDIS;

ADHESINS, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; GENETIC VARIATION; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PHENOTYPE; PORINS; PREVALENCE; QUEBEC; SEROTYPING;

EID: 84937924931     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/s12866-015-0469-6     Document Type: Article

References (37)

1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Huges JM. Meningococcal disease. N Engl J Med. 2001;344:1378-88.
2. Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. J Trop Med. 2010;17(Suppl):3-8.
3. Xie Q, Pollard AJ, Mueller JE, Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine. 2013;31:2852-61.
4. Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS. 1998;106:505-25.
5. Yazdankhah SP, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, Musilek M, et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol. 2014;42:5146-53.
6. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27:B51-63.
7. Harrison OB, Brueggemann AB, Caugant DA, van der Ende A, Frosch M, Tray S, et al. Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae, a review. Microbiolology. 2011;157:2181-95.
8. Thompson EA, Feavers IM, Maiden MC. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology. 2003;149:1849-58.
9. Warshawsky B. Update on the use of quadrivalent meningococcal vaccines. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization. Can Comm Dis Rep. 2013;39(ACS-1):1-40.
10. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;322:355-7.
11. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. 2000;287:1809-15.
12. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity. 2010;33:530-41.
13. Perez-Trallero E, Esnal O, Marimon JM. Progressive decrease in the potential useflness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northers Spain. PLoS One. 2014;9, e116024.
14. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuloi R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30 Suppl 2:B87-97.
15. Richmond PC, Marshall HS, Nissan MD, Jiang Q, Jansen KJ, Garces-Sanchez M, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomized, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12:597-607.
16. Oster P, Lennon D, O'Hallahan MK, Reid S, Martin D. MeNZB™: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005;23:2191-6.
17. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72:2088-100.
18. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197:789-99.
19. Giuliana MM, Adu-Bobie J, Commanducci M, Arico B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA. 2006;103:10834.
20. Bambini S, De Chiara M, Muzzi A, Mora M, Lucidarme J, Brehony C, et al. Neisseria Adhesin A variation and revised nomenclature scheme. Clin Vaccine Immunol. 2014;21:966-71.
21. Gilca R, Deceuninck G, Lefebvre B, Tsang R, Amin R, Gilca V, et al. The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains. PLoS One. 2012;7, e50659.
22. Abdillahi H, Poolman JT. Whole-cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol Lett. 1987;48:367-71.
23. Maiden MCJ, Bygraves JA, Feil E, Morelli E, Russell JE, Urwin R, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA. 1998;95:3140-5.
24. Sacchi CT, Lemos AP, Brandt ME, Whitney AM, Melles CEA, Solari CA, et al. Proposed standardization of Neisseria meningitidis PorA variable-region typing nomemclature. Clin Diagn Lab Immunol. 1998;5:845-55.
25. Clark SC, Diggle MA, Molling P, Unemo M, Olcen P. Analysis of PorA variable region 3 in menincococci: implications for vaccine policy. Vaccine. 2003;21:2468-73.
26. De Filippis I, Gopalan V, Huyen Y. PorA VR3 typing database: a web-based resource for the determination of PorA VR3 alleles of Neisseria meningitidis. Infect Gene Evol. 2011;11:248-9.
27. Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST-269 clonal complex isolates from England and Wales. J Clin Microbiol. 2009;47:3577-85.
28. Lucidarme J, Tan L, Exley RM, Findlow J, Borrow R, Tang CM. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol. 2011;18:1002-14.
29. Law DKS, Lorange M, Ringuette L, Dion R, Giguere M, Henderson AM, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol. 2006;44:2743-9.
30. Zhou J, Lefebvre B, Deng S, Gilca R, Deceuninck G, Law DKS, et al. Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. J Clin Microbiol. 2012;50:1545-51.
31. Tsang RSW, Jamieson FB, Lefebvre B, Gilca R. Emerging sequence type-269 serogroup B Neisseria meningitidis has the potential to cause outbreaks. Can J Infect Dis Med Microbiol. 2014;25:8.
32. Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine. 2014;32:124-30.
33. Law DKS, Zhou J, Deng S, Hoang L, Tyrrell G, Horsman G, et al. Determination of serotyping antigens, clonal analysis and genetic characterization of the 4CMenB vaccine antigen genes in invasive Neisseria meningitidis from Western Canada, 2009-2013. J Med Microbiol. 2014;63:1490-9.
34. Tsang RSW, Hoang L, Tyrrell G, Horsman G, Wylie J, Jamieson F, et al. Genetic and antigenic characterization of Canadian Neisseria meningitidis serogroup C (MenC) case isolates in the post-MenC conjugate vaccine era, 2009-2013. J Med Microbiol. 2015;64:174-9.
35. Elias J, Vogel U. IS1301 fingerprint analysis of Neisseria meningitidis strains belonging to the ET-15 clone. J Clin Microbiol. 2007;45:159-67.
36. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Québec, Canada, 1990-1994. Clin Infect Dis. 1998;26:1159-64.
37. COMITÉ SUR L'IMMUNISATION DU QUÉBEC. Avis du Comité sur l'immunisation du Québec concernant l'utilité d'une dose de rappel de vaccin contre le méningocoque chez les adolescents au Québec. INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC, Québec: 2010. Available at: http://www.inspq.qc.ca/pdf/publications/1178-AvisCIQDoseRappelMeningocoqueAdos.pdf.